Use of 1,3-β-D-glucan in invasive fungal diseases in hematology patients

References

• Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the gruppo italiano trapianto midollo osseo (gitmo). Biol Blood Marrow Transplant. 2014;20:872–880.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (transnet) database. Clin Infect Dis. 2010;50:1091–1100.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Bories P, Moulin JC, et al. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci. 2012;1272:23–30.
   PubMed Web of Science ®Google Scholar
• Colombo AL, De Almeida Júnior JN, Slavin MA, et al. Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer. Lancet Infect Dis. 2017;17:e344-e356. Epub ahead of print. DOI:10.1016/S1473-3099(17)30304-3
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–4366.
   PubMed Web of Science ®Google Scholar
• Shaukat A, Bakri F, Young P, et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia. 2005;159:181–188.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Gachot B, Akan H, et al. Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis. 2015;61:324–331.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Gangneux J-P, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect. 2011;17:1882–1889.
   PubMed Web of Science ®Google Scholar
• Kyvernitakis A, Torres HA, Jiang Y, et al. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016;22:811.e1–811.e8.
   PubMed Web of Science ®Google Scholar
• Chitasombat MN, Kofteridis DP, Jiang Y, et al. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect. 2012;64:68–75.
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–851.
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96:2055–2061.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–347.
   PubMed Web of Science ®Google Scholar
• Martino R, Viscoli C. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol. 2005;132:138–154.
   Web of Science ®Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101–111.
   PubMed Web of Science ®Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med. 1989;86:668–672.
   PubMed Web of Science ®Google Scholar
• De Pauw B. Between over- and undertreatment of invasive fungal disease. Clin Infect Dis. 2005;41:1251–1253.
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242–1250.
   PubMed Web of Science ®Google Scholar
• Maertens J, Deeren D, Dierickx D, et al. Preemptive antifungal therapy: still a way to go. Curr Opin Infect Dis. 2006;19:551–556.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Marchetti O, Lamoth F, Mikulska M, et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47:846–854.
   PubMed Web of Science ®Google Scholar
• Pope C, Ziebland S, Mays N. Qualitative research in health care. Analyzing qualitative data. BMJ. 2000;320:114–116.
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199–205.
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Paetznick VL, Rodriguez JR, et al. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol. 2006;44:267–272.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Obayashi T, Iwama A, et al. Detection of plasma (1-3)-beta-D-glucan in patients with Fusarium, Trichosporon, Saccharomyces and Acremonium fungaemias. J Med Vet Mycol. 1997;35:371–374.
   PubMedGoogle Scholar
• Obayashi T, Yoshida M, Mori T, et al. Plasma (1–>3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet. 1995;345:17–20.
   PubMed Web of Science ®Google Scholar
• Ochi Y, Hiramoto N, Takegawa H, et al. Infective endocarditis caused by Scedosporium prolificans infection in a patient with acute myeloid leukemia undergoing induction chemotherapy. Int J Hematol. 2015 Jun;101(6):620–625.
   PubMed Web of Science ®Google Scholar
• Kauffmann-Lacroix C, Rodier MH, Jacquemin JL, et al. Detection of galactomannan for diagnosis of fungal rhinosinusitis. J Clin Microbiol. 2001;39:4593–4594.
   PubMed Web of Science ®Google Scholar
• Cuétara MS, Alhambra A, Moragues MD, et al. Detection of (1–>3)-beta-D-glucan as an adjunct to diagnosis in a mixed population with uncommon proven invasive fungal diseases or with an unusual clinical presentation. Clin Vaccine Immunol. 2009;16:423–426.
   PubMed Web of Science ®Google Scholar
• Fekkar A, Brun S, D’Ussel M, et al. Serum cross-reactivity with Aspergillus galactomannan and cryptococcal antigen during fatal disseminated Trichosporon dermatis infection. Clin Infect Dis. 2009;49:1457–1458.
   PubMed Web of Science ®Google Scholar
• Egan L, Connolly P, Wheat LJ, et al. Histoplasmosis as a cause for a positive Fungitell (1 –> 3)-beta-D-glucan test. Med Mycol. 2008;46:93–95.
   PubMed Web of Science ®Google Scholar
• Cummings JR, Jamison GR, Boudreaux JW, et al. Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis. 2007;59:113–115.
   PubMed Web of Science ®Google Scholar
• Huang YT, Hung CC, Liao CH, et al. Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus. J Clin Microbiol. 2007;45:2858–2862.
   PubMed Web of Science ®Google Scholar
• Giacchino M, Chiapello N, Bezzio S, et al. Aspergillus galactomannan enzyme-linked immunosorbent assay cross-reactivity caused by invasive Geotrichum capitatum. J Clin Microbiol. 2006;44:3432–3434.
   PubMed Web of Science ®Google Scholar
• Rivière S, Denis B, Bougnoux ME, et al. Serum Aspergillus galactomannan for the management of disseminated histoplasmosis in AIDS. Am J Trop Med Hyg. 2012;87:303–305.
   PubMed Web of Science ®Google Scholar
• Girouard G, Lachance C, Pelletier R. Observations on (1-3)-beta-D-glucan detection as a diagnostic tool in endemic mycosis caused by histoplasma or blastomyces. J Med Microbiol. 2007;56:1001–1002.
   PubMed Web of Science ®Google Scholar
• Gr T 3rd, Dj B, Sm J, et al. Serum (1->3)-β-D-glucan measurement in coccidioidomycosis. J Clin Microbiol. 2012;50:3060–3062.
   PubMed Web of Science ®Google Scholar
• Assi M, Lakkis IE, Wheat LJ. Cross-reactivity in the Histoplasma antigen enzyme immunoassay caused by sporotrichosis. Clin Vaccine Immunol. 2011;18:1781–1782.
   PubMed Web of Science ®Google Scholar
• LeibundGut-Landmann S, Wüthrich M, Hohl TM. Immunity to fungi. Curr Opin Immunol. 2012;24:449–458.
   PubMed Web of Science ®Google Scholar
• Wang Y. Looking into Candida albicans infection, host response, and antifungal strategies. Virulence. 2015;6:307–308.
   PubMed Web of Science ®Google Scholar
• Poulain D, Jouault T. Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk. Curr Opin Microbiol. 2004;7:342–349.
   PubMed Web of Science ®Google Scholar
• Lamoth F, Cruciani M, Mengoli C, et al. b-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633–643.
   PubMed Web of Science ®Google Scholar
• Desmet S, Van Wijngaerden E, Maertens J, et al. Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol. 2009;47:3871–3874.
   PubMed Web of Science ®Google Scholar
• Obayashi T, Yoshida M, Tamura H, et al. Determination of plasma (1/3)-β-D-glucan: a new diagnostic aid to deep mycosis. J Med Vet Mycol. 1992;30:275–280.
   PubMedGoogle Scholar
• Obayashi T, Negishi K, Suzuki T, et al. Reappraisal of the serum (1–>3)-β-D-glucan assay for the diagnosis of invasive fungal infections—a study based on autopsy cases from 6 years. Clin Infect Dis. 2008;46:1864–1870.
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004;4(6):349–357.
   PubMed Web of Science ®Google Scholar
• Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD007394. doi: 10.1002/14651858.CD007394..
   PubMed Web of Science ®Google Scholar
• Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42:1417–1427.
   PubMed Web of Science ®Google Scholar
• Sulahian A, Porcher R, Bergeron A, et al. Use and limits of (1-3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. J Clin Microbiol. 2014;52:2328–2333.
   PubMed Web of Science ®Google Scholar
• Ceesay MM, Desai SR, Berry L, et al. A comprehensive diagnostic approach using galactomannan, targeted β-d-glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients. Br J Haematol. 2015;168:219–229.
   PubMed Web of Science ®Google Scholar
• Hachem RY, Kontoyiannis DP, Chemaly RF, et al. Utility of galactomannan enzyme immunoassay and (1,3)beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol. 2009;47:129–133.
   PubMed Web of Science ®Google Scholar
• Metan G, Koc AN, Kaynar LG, et al. What is the role of the (1,3)-beta-D-glucan assay in the screening of patients undergoing autologous haematopoietic stem-cell transplantation? Mycoses. 2013;56(1):34–38.
   PubMed Web of Science ®Google Scholar
• Pazos C, Pontón J, Del Palacio A. Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol. 2005;43:299–305.
   PubMed Web of Science ®Google Scholar
• Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1–>3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol. 2004;42:2733–2741.
   PubMed Web of Science ®Google Scholar
• Reischies FM, Prattes J, Woelfler A, et al. Diagnostic performance of 1,3-beta-D-glucan serum screening in patients receiving hematopoietic stem cell transplantation. Transpl Infect Dis. 2016;18:466–470.
   PubMed Web of Science ®Google Scholar
• Metan G, Keklik M, Dinç G, et al. Performance of galactomannan antigen, beta-d-glucan, and aspergillus-lateral-flow device for the diagnosis of invasive aspergillosis. Indian J Hematol Blood Transfus. 2017;33:87–92.
   PubMed Web of Science ®Google Scholar
• Ellis M, Al-Ramadi B, Finkelman M, et al. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol. 2008;57:287–295.
   PubMed Web of Science ®Google Scholar
• Bertz H, Drognitz K, Finke J. Analysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: “real life” evaluation. Ann Hematol. 2016;95:457–463.
   PubMed Web of Science ®Google Scholar
• Pini P, Bettua C, Orsi CF, et al. Evaluation of serum (1 → 3)-β-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors. Infection. 2016;44:223–233.
   PubMed Web of Science ®Google Scholar
• Hammarström H, Kondori N, Friman V, et al. How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors. Eur J Clin Microbiol Infect Dis. 2015;34:917–925.
   PubMed Web of Science ®Google Scholar
• Senn L, Robinson JO, Schmidt S, et al. 1,3-ß-D-Glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46:878–885.
   PubMed Web of Science ®Google Scholar
• Metan G, Koc AN, Atalay A, et al. What should be the optimal cut-off of serum 1,3-beta-D-glucan for the detection of invasive pulmonary aspergillosis in patients with haematological malignancies? Scand J Infect Dis. 2012;44:330–336.
   PubMed Web of Science ®Google Scholar
• Schwarzinger M, Sagaon-Teyssier L, Cabaret O, et al. Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model. PLoS One. 2013;8:e65776.
   PubMed Web of Science ®Google Scholar
• Lunel FM, Mennink-Kersten MA, Ruegebrink D, et al. Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. Diagn Microbiol Infect Dis. 2009;64:408–415.
   PubMed Web of Science ®Google Scholar
• Pazos C, Moragues MD, Quindós G, et al. Diagnostic potential of (1→3)-ß-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol. 2006;23:209–215.
   PubMedGoogle Scholar
• Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis. 2011;52:750–770.
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen YQ, Guo YL, et al. Diagnosis of invasive fungal disease using serum (1,3)-β-D-glucan: a bivariate meta-analysis. Intern Med. 2011;50:2783–2791.
   PubMed Web of Science ®Google Scholar
• Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-β-D-glucan for Pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol. 2012;50:7–15.
   PubMed Web of Science ®Google Scholar
• Vena A, Bouza E, Álvarez-Uría A, et al. The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin. Clin Microbiol Infect. 2017. Epub ahead of print. DOI:10.1016/j.cmi.2017.05.006
   Google Scholar
• Duarte RF, Sánchez-Ortega I, Cuesta I, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014;59:1696–1702.
   PubMed Web of Science ®Google Scholar
• Iwama A, Yoshida M, Miwa A, et al. Improved survival from fungaemia in patients with haematological malignancies: analysis of risk factors for death and usefulness of early antifungal therapy. Eur J Haematol. 1993;51:156–160.
   PubMed Web of Science ®Google Scholar
• Azoulay E, Guigue N, Darmon M, et al. (1, 3)-β-D-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies. Oncotarget. 2016;7:21484–21495.
   PubMed Web of Science ®Google Scholar
• Persat F, Ranque S, Derouin F, et al. Contribution of the (1 – > 3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2008;46:1009–1013.
   PubMed Web of Science ®Google Scholar
• Lahmer T, Rasch S, Schnappauf C, et al. Comparison of serum galactomannan and 1,3-beta-d-glucan determination for early detection of invasive pulmonary aspergillosis in critically ill patients with hematological malignancies and septic shock. Mycopathologia. 2016;181:505–511.
   PubMed Web of Science ®Google Scholar
• Koo S, Bryar JM, Page JH, et al. Diagnostic performance of the (1–>3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis. 2009;49:1650–1659.
   PubMed Web of Science ®Google Scholar
• Del Bono V, Delfino E, Furfaro E, et al. Clinical performance of the (1,3)-beta-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol. 2011;18:2113–2117.
   PubMed Web of Science ®Google Scholar
• Pickering J, Sant H, Bowles C, et al. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol. 2015;43:5957–5962.
   Google Scholar
• Fontana C, Gaziano R, Favaro M, et al. (1-3)-β-D-glucan vs galactomannan antigen in diagnosing invasive fungal infections (IFIs). Open Microbiol J. 2012;6:70–73.
   PubMedGoogle Scholar
• Bellanger AP, Grenouillet F, Henon T, et al. Retrospective assessment of β-D-(1,3)-glucan for presumptive diagnosis of fungal infections. Apmis. 2011;119:280–286.
   PubMed Web of Science ®Google Scholar
• Mori T, Matsumura M. Clinical evaluation of diagnostic methods using plasma and/or serum for three mycoses: aspergillosis, candidosis, and pneumocystosis. Nihon Ishinkin Gakkai Zasshi. 1999;40:223–230.
   PubMedGoogle Scholar
• Karageorgopoulos DE, Qu JM, Korbila IP, et al. Accuracy of beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect. 2013;19:39–49.
   PubMed Web of Science ®Google Scholar
• Damiani C, Le Gal S, Lejeune D, et al. Serum (1->3)-beta-D-glucan levels in primary infection and pulmonary colonization with Pneumocystis jirovecii. J Clin Microbiol. 2011;49:2000–2002.
   PubMed Web of Science ®Google Scholar
• Theel ES, Doern CD. β-D-glucan testing is important for diagnosis of invasive fungal infections. J Clin Microbiol. 2013;51: 3478–3483. Clin. Microbiol. Infect. 2013;19:39–49.
   PubMed Web of Science ®Google Scholar
• Del Bono V, Mularoni A, Furfaro E, et al. Clinical evaluation of a (1,3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol. 2009;16:1524–1526.
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY, Nguyen NP, et al. Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow transplant setting: a follow-up study. Cancer. 2001;92:1349–1353.
   PubMed Web of Science ®Google Scholar
• Gamaletsou MN, Walsh TJ, Zaoutis T, et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect. 2014;20:O50–7.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Mikulska M, Tumbarello M, et al. Combined use of serum (1,3)-β-D-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. Crit Care. 2017;21:176.
   PubMed Web of Science ®Google Scholar
• Posteraro B, Tumbarello M, De Pascale G, et al. (1,3)-β-D-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. J Antimicrob Chemother. 2016;71:2262–2269.
   PubMed Web of Science ®Google Scholar
• Nucci M, Nouèr SA, Esteves P, et al. Discontinuation of empirical antifungal therapy in ICU patients using 1,3-β-D-glucan. J Antimicrob Chemother. 2016;71:2628–2633.
   PubMed Web of Science ®Google Scholar
• Jaijakul S, Vazquez JA, Swanson RN, et al. (1,3)-ß-D-Glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55:521–526.
   PubMed Web of Science ®Google Scholar
• Angebault C, Lanternier F, Dalle F, et al. Prospective evaluation of serum β-glucan testing in patients with probable or proven fungal diseases. Open Forum Infect Dis. 2016;3:ofw128.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Railkar R, Mullane KM, et al. Correlation between circulating fungal biomarkers and clinical outcome in invasive aspergillosis. PLoS One. 2015;10:e0129022.
   PubMed Web of Science ®Google Scholar
• Sims CR, Jaijakul S, Mohr J, et al. Correlation of clinical outcomes with beta-glucan levels in patients with invasive candidiasis. J Clin Microbiol. 2012;50:2104–2106.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Esteves P, Bruzzi P, et al. Initial serum (1,3)-β-D-glucan as a predictor of mortality in proven candidaemia: findings from a retrospective study in two teaching hospitals in Italy and Brazil. Clin Microbiol Infect. 2015;21:954.e9–17.
   Google Scholar
• Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis. 2011;11:76.
   PubMed Web of Science ®Google Scholar
• Marty FM, Koo S, Bryar J, et al. (1→3)beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med. 2007;147:70–72.
   PubMed Web of Science ®Google Scholar
• Held J, Wagner D. β-D-Glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia. Clin Microbiol Infect. 2011;17:1118–2273.
   PubMed Web of Science ®Google Scholar
• Yasuoka A, Tachikawa N, Shimada K, et al. (1–.3) β-D-Glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol. 1996;3:197–199.
   PubMedGoogle Scholar
• Alanio A, Hauser PM, Lagrou K, et al. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2386–2396.
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Mori T, Hashida R, et al. False-positive serum (1, 3)-β-D-glucan elevation due to intake of seaweed in a hematopoietic stem cell transplant recipient. Transpl Infect Dis. 2017;19:e12653. Epub ahead of print. DOI:10.1111/tid.12653
   Web of Science ®Google Scholar
• Racil Z, Kocmanova I, Lengerova M, et al. Difficulties in using 1,3-{beta}-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies–high frequency of false-positive results and their analysis. J Med Microbiol. 2010;59:1016–1022.
   PubMed Web of Science ®Google Scholar
• Marty FM, Lowry CM, Lempitski SJ, et al. Reactivity of (1→3)-β-D-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother. 2006;50:3450–3453.
   PubMed Web of Science ®Google Scholar
• Usami M, Ohata A, Horiuchi T, et al. Positive (1–>3)-beta-D-glucan in blood components and release of (1–>3)-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion. 2002;42:1189–1195.
   PubMed Web of Science ®Google Scholar
• Nagasawa K, Yano T, Kitabayashi G, et al. Experimental proof of contamination of blood components by (1–>3)-beta-D-glucan caused by filtration with cellulose filters in the manufacturing process. J Artif Organs. 2003;6:49–54.
   PubMedGoogle Scholar
• Duffner U, Abdel-Mageed A, Dahl K, et al. Serum (1□3)-beta-D-glucan levels (Fungitell assay) is not useful as a screening test for recipients of an allogeneic HSCT while on immunoglobulin replacement. Bone Marrow Transplant. 2012;47:151–152.
   PubMed Web of Science ®Google Scholar
• Nakao A, Yasui M, Kawagoe T, et al. False-positive endotoxemia derives from gauze glucan after hepatectomy for hepatocellular carcinoma with cirrhosis. Hepatogastroenterology. 1997;44:1413–1418.
   PubMed Web of Science ®Google Scholar
• Koncan R, Favuzzi V, Ligozzi M, et al. Cross-reactivity of Nocardia spp. in the fungal (1,3)-beta-d-glucan assay performed on cerebral spinal fluid. Diagn Microbiol Infect Dis. 2015;81(2):94–95.
   PubMed Web of Science ®Google Scholar
• Otto GP, Ludewig K, Jacobsen ID, et al. Limitation of (1,3)-beta-D-glucan monitoring in major elective surgery involving cardiopulmonary bypass. Crit Care. 2013;17(3):437.
   PubMed Web of Science ®Google Scholar
• Furfaro E, Viscoli C, Giacobbe DR, et al. The beta-d-glucan test: time to re-visit its utility in IFI diagnosis. Curr Fungal Infect Rep. 2015;9:292–301.
   Web of Science ®Google Scholar
• Digby J, Kalbfleisch J, Glenn A, et al. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol. 2003;10:882–885.
   PubMedGoogle Scholar
• Albert O, Toubas D, Strady C, et al. Reactivity of (1□3)-ß-D-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis. 2011;30:1453–1460.
   PubMed Web of Science ®Google Scholar
• Prattes J, Raggam RB, Vanstraelen K, et al. Chemotherapy-induced intestinal mucosal barrier damage: a cause of falsely elevated serum 1,3-beta-d-glucan levels? J Clin Microbiol. 2016;54:798–801.
   PubMed Web of Science ®Google Scholar
• Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007;61:208–221.
   PubMed Web of Science ®Google Scholar
• Sendid B, Francois N, Decool V, et al. Strategy for overcoming serum interferences in detection of serum (1,3)-beta-D-glucans. J Clin Microbiol. 2013;51:375–376.
   PubMed Web of Science ®Google Scholar
• Parsons SK, Skapek SX, Neufeld EJ, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood. 1997;89:1886–1895.
   PubMed Web of Science ®Google Scholar
• Prattes J, Schneditz D, Prüller F, et al. 1,3-ß-d-Glucan testing is highly specific in patients undergoing dialysis treatment. J Infect. 2017;74:72–80.
   PubMed Web of Science ®Google Scholar
• Liss B, Cornely OA, Hoffmann D, et al. 1,3-ß-D-glucan concentrations in blood products predict false positive post-transfusion results. Mycoses. 2016;59:39–42.
   PubMed Web of Science ®Google Scholar
• Kanamori H, Kanemitsu K, Miyasaka T, et al. Measurement of (1-3)-beta-D-glucan derived from different gauze types. Tohoku J Exp Med. 2009;217:117–121.
   PubMed Web of Science ®Google Scholar
• Metan G, Agkus C, Nedret Koc A, et al. Does ampicillin-sulbactam cause false positivity of (1,3)-beta-D-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections. Mycoses. 2012;55:366–371.
   PubMed Web of Science ®Google Scholar
• Furfaro E, Mikulska M, Del Bono V, et al. Infections are an improbable cause of positive serum (1,3)-beta-D-glucan in hematology patients. Clin Vaccine Immunol. 2014;21:1357–1359.
   PubMed Web of Science ®Google Scholar
• Metan G, Koc AN, Ağkuş Ç, et al. Can bacteraemia lead to false positive results in 1,3-beta-D-glucan test? Analysis of 83 bacteraemia episodes in high-risk patients for invasive fungal infections. Rev Iberoam Micol. 2012;29:169–171.
   PubMed Web of Science ®Google Scholar
• Racil Z, Kocmanova I, Toskova M, et al. Reactivity of the 1,3-ß-D-glucan assay during bacteraemia: limited evidence from a prospective study. Mycoses. 2013;56:101–104.
   PubMed Web of Science ®Google Scholar
• Abe M, Kimura M, Araoka H, et al. Serum (1,3)-beta-D-glucan is an inefficient marker of breakthrough candidemia. Med Mycol. 2014;52:835–840.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Giacobbe DR, Furfaro E, et al. Lower sensitivity of serum (1,3)-beta-D-glucan for the diagnosis of candidaemia due to Candida parapsilosis. Clin Microbiol Infect. 2016;22:646. e5–8.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1,3)-β-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654e9.
   Web of Science ®Google Scholar
• Liu Y, Chen F, Zhu X, et al. Evaluation of a novel plasma (1,3)-β-d-glucan detection assay for diagnosis of candidemia in pediatric patients. J Clin Microbiol. 2015;53:3017e20.
   Web of Science ®Google Scholar
• Mikulska M, Furfaro E, Del Bono V, et al. (1,3)-beta-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. Clin Infect Dis. 2013;56:1511–1512.
   PubMed Web of Science ®Google Scholar
• Litvintseva AP, Lindsley MD, Gade L, et al. Utility of (1,3)-beta-D-glucan testing for diagnostics and monitoring response to treatment during the multistate outbreak of fungal meningitis and other infections. Clin Infect Dis. 2014;58:622–630.
   PubMed Web of Science ®Google Scholar
• Lyons JL, Thakur KT, Lee R, et al. Utility of measuring (1,3)-beta-d-glucan in cerebrospinal fluid for diagnosis of fungal central nervous system infection. J Clin Microbiol. 2015;53(1):319–322.
   PubMed Web of Science ®Google Scholar
• Rhein J, Bahr NC, Morawski BM, et al. Detection of high cerebrospinal fluid levels of (1,3)-beta-d-glucan in cryptococcal meningitis. Open Forum Infect Dis. 2014 Dec;1(3):ofu105.
   PubMedGoogle Scholar
• Hoenigl M, Prattes J, Spiess B, et al. Performance of galactomannan, beta-d-glucan, aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2014;52:2039–2045.
   PubMed Web of Science ®Google Scholar
• Theel ES, Jespersen DJ, Iqbal S, et al. Detection of (1,3)-beta-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia. 2013;75(1–2):33–41.
   Google Scholar
• Damiani C, Le Gal S, Goin N, et al. Usefulness of (1,3) ß-D-glucan detection in bronchoalveolar lavage samples in Pneumocystis pneumonia and Pneumocystis pulmonary colonization. J Mycol Med. 2015;25:36–43.
   PubMed Web of Science ®Google Scholar
• Damiani C, Le Gal S, Da Costa C, et al. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1,3)-beta-D-glucan for differential diagnosis of Pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol. 2013;51:3380–3388.
   PubMed Web of Science ®Google Scholar
• Tasaka S, Kobayashi S, Yagi K, et al. Serum (1,3) beta-D-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization. J Infect Chemother. 2014;20:678–681.
   PubMed Web of Science ®Google Scholar
• Raggam RB, Fischbach LM, Prattes J, et al. Detection of (1→3)-β-D-glucan in same-day urine and serum samples obtained from patients with haematological malignancies. Mycoses. 2015;58:394–398.
   PubMed Web of Science ®Google Scholar
• Boch T, Spiess B, Cornely OA, et al. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. Clin Microbiol Infect. 2016;22:862–868.
   PubMed Web of Science ®Google Scholar
• Farina C, Lombardi G, Andreoni S, et al. Routine use of a protease zymogen-based colorimetric assay for the detection of beta-glucan and its role in clinical practice. Int J Immunopathol Pharmacol. 2014;27(4):661–668.
   PubMed Web of Science ®Google Scholar
• Charles PE, Dalle F, Aho S, et al. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med. 2006;32:1577–1583.
   PubMed Web of Science ®Google Scholar
• Martini A, Gottin L, Menestrina N, et al. Procalcitonin levels in surgical patients at risk of candidaemia. J Infect. 2010;60:425–430.
   PubMed Web of Science ®Google Scholar
• Cortegiani A, Russotto V, Montalto F, et al. Procalcitonin as a marker of Candida species detection by blood culture and polymerase chain reaction in septic patients. BMC Anesthesiol. 2014;14:9.
   PubMed Web of Science ®Google Scholar
• Martínez-Jiménez MC, Muñoz P, Valerio M, et al. Candida biomarkers in patients with candidaemia and bacteraemia. J Antimicrob Chemother. 2015;70:2354–2361.
   PubMed Web of Science ®Google Scholar
• Martínez-Jiménez MC, Muñoz P, Valerio M, et al. Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment. J Antimicrob Chemother. 2015;70(11):3107–3115.
   PubMed Web of Science ®Google Scholar
• Mery A, Sendid B, François N, et al. Application Of Mass Spectrometry Technology To Early Diagnosis Of Invasive Fungal Infections. J Clin Microbiol. 2016;54:2786–2797.
   Google Scholar
• Brasier AR, Zhao Y, Spratt HM, et al. Improved detection of invasive pulmonary aspergillosis arising during leukemia treatment using a panel of host response proteins and fungal antigens. PLoS One. 2015;10:e0143165.
   PubMed Web of Science ®Google Scholar
• Badiee P, Alborzi A, Karimi M, et al. Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients. J Infect Dev Ctries. 2012;6:352–357.
   PubMed Web of Science ®Google Scholar
• Koltze A, Rath P, Schoning S, et al. Beta-D-glucan screening for detection of invasive fungal disease in children undergoing allogeneic hematopoietic stem cell transplantation. J Clin Microbiol. 2015;53:2605–2610.
   PubMed Web of Science ®Google Scholar
• Mokaddas E, Burhamah MH, Khan ZU, et al. Levels of (1–>3)-beta-D-glucan, Candida mannan and Candida DNA in serum samples of pediatric cancer patients colonized with Candida species. BMC Infect Dis. 2010;10:292–2334.10–292.
   PubMed Web of Science ®Google Scholar
• Smith PB, Jr DK B, Alexander BD, et al. Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol. 2007;14:924–925.
   PubMed Web of Science ®Google Scholar
• Warris A, Lehrnbecher T. Progress in the diagnosis of invasive fungal disease in children. Curr Fungal Infect Rep. 2017;11:35–44.
   PubMed Web of Science ®Google Scholar
• Guitard J, Tabone MD, Senghor Y, et al. Detection of β-D-glucan for the diagnosis of invasive fungal infection in children with hematological malignancy. J Infect. 2016;73:607–615.
   PubMed Web of Science ®Google Scholar
• Calitri C, Caviglia I, Cangemi G, et al. Performance of 1,3-β-D-glucan for diagnosing invasive fungal diseases in children. Mycoses. 2017. Epub ahead of print. DOI:10.1111/myc.12664
   PubMedGoogle Scholar
• Lehrnbecher T, Robinson PD, Fisher BT, et al. Galactomannan, β-D-glucan, and polymerase chain reaction-based assays for the diagnosis of invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review and meta-analysis. Clin Infect Dis. 2016;63:1340–1348.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Phillips R, Alexander S, et al. Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;30:4427–4438.
   PubMed Web of Science ®Google Scholar
• Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327–40.
   PubMed Web of Science ®Google Scholar
• Prüller F, Wagner J, Raggam RB, et al. Automation of serum (1→3)-beta-D-glucan testing allows reliable and rapid discrimination of patients with and without candidemia. Med Mycol. 2014;52:455–461.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Nucci M, Donnelly JP. The role of antifungal treatment in hematology. Haematologica. 2012;97:325–327.
   PubMed Web of Science ®Google Scholar